SDPA Fall | Live Blog | Product Theater Sponsored by Novartis Pharmaceuticals
Product Theater | “COSENTYX® (secukinumab) for the Ongoing Management of Adult Patients with Moderate to Severe Plaque Psoriasis and Active Psoriatic Arthritis.”
Sponsored by: Novartis Pharmaceuticals
Presented by: live Lui, MD
At this morning’s product theater (during the SDPA’s 14th Annual Fall Dermatology Conference), Dr. Clive Liu, MD presented “COSENTYX® (secukinumab) for the Ongoing Management of Adult Patients with Moderate to Severe Plaque Psoriasis and Active Psoriatic Arthritis.” Dr. Liu explained that 1 in 10 patients with psoriasis are diagnosed with psoriatic arthritis, though it is estimated that up to 30% of patients with psoriasis have psoriatic arthritis, and that the difference between those rates are likely due to providers not catching arthritis as early as we can. He also discussed the symptom of itching in patients with psoriasis occurs in up to 40% of patients with psoriasis and describe it as the “most irritating and annoying symptom”.
Dr. Liu went on to describe the use of Cosentyx®, the first and only human monoclonal antibody targeting IL-17A approved for both moderate to severe psoriasis and active psoriatic arthritis. Data from three years of use with Cosentyx® showed this medication leads to clearer skin in the majority of patients with psoriasis, with a high proportion of patients achieving a PASI of 75. Dr. Liu also highlighted that patients with psoriatic arthritis have experienced improvement in their symptoms as well as improvement in their skin lesions when they have coexistent plaques. The most common side effects of Cosentyx® are nasopharyngitis, diarrhea and upper respiratory infections. Cosentyx® is given as a subcutaneous injection. Dosing for plaque psoriasis is 300mg SQ weekly x 4 weeks, then monthly. For psoriatic arthritis, the dosing is 150mg SQ weekly x 4 weeks, then monthly.
Finally, Dr. Liu states that Cosentyx® improves the symptoms of itching in patients.
Byline: Sarah Patton, PA-C, MSHS
Posted: November 4, 2016